Posted inStock
Xenon Pharmaceuticals (XENE) Surges 45% After Positive Trial Results for Epilepsy Drug Azetukalner
Xenon Pharmaceuticals Inc. (XENE) stock soared by 45.82% following the announcement of promising Phase 3 trial results for its epilepsy drug, azetukalner, showing a significant reduction in focal onset seizures…







